Performance of a self-expanding stent specifically designed for percutaneous arterial duct stenting for the “Gießen hybrid” procedure for primary treatment of complex congenital heart defects

Kerst G., Mienert T., Khalil M., Yerebakanc C., Akintürk H., Schranz D.
Pediatric Heart Center Giessen, Justus-Liebig-University, Giessen, Germany

Objectives:
To report on our 5-year single-center experience with a specifically designed self-expanding stent for the arterial duct for the “Gießen hybrid” procedure in complex congenital heart disease (CCHD).

Methods:

Results:
52 newborns underwent the “Gießen hybrid” procedure with uneventful percutaneous arterial duct stenting for primary treatment of CCHD (hypoplastic left heart syndrome/complex (HLHS/HLHC), n = 30/16; others, n = 6) at a median age of 6 days (range 1 – 50) with a median weight of 3.0 kg (range 1.9 – 4.4; n = 9 ≤2500g) and a median Aristotle score of 17.0 (range 14.5 – 21.5). Implantation of a second stent to completely cover the arterial duct was necessary in 8 patients. Duct restenosis treated by balloon dilation and/or implantation of a second stent occurred in 13 patients. 26 patients underwent comprehensive stage II palliation, 10 received biventricular repair, 13 are on inter-stage of which 3 are planned for biventricular repair. Heart transplantation was performed in two patients (pt #1 with severely hypoplastic ascending aorta and signs of cardiac ischemia, pt #2 with HLHC and non-compaction cardiomyopathy). Inter-stage mortality occurred in one patient with hypoplastic left heart syndrome and coarctation of the aorta due to cardiac ischemia.

Conclusions:
The Sinus-Superflex-DS received a CE-mark for percutaneous arterial duct stenting in newborns. The low profile and open cell design allows usage with low risk and is easily positioned by arterial access through a 4 Fr sheath. However, in some cases the low radial power of the self-expanding stent requires balloon re-dilation.